Clincosm LogoSign in Get a demo

Evaluation of the Epidermal Langerhans Cell Population in AIDS / ARC Patients by the Topical Application of a Potent Contact Allergen (1-Chloro-2,4-Dinitro-Chlorobenzene) (DNCB)

Sponsor
University of California, San Francisco (Other)
Overall Status
Completed
CT.gov ID
NCT00002031
Collaborator
(none)
1
Location

Study Details

Study Description

Brief Summary

To evaluate the effect of application of Dinitrochlorobenzene (DNCB) on the number, morphology, and antigen expression of epidermal Langerhans cells in AIDS and AIDS related complex (ARC) patients.

Condition or Disease Intervention/Treatment Phase
N/A

Study Design

Study Type:
Interventional
Primary Purpose:
Treatment
Official Title:
Evaluation of the Epidermal Langerhans Cell Population in AIDS / ARC Patients by the Topical Application of a Potent Contact Allergen (1-Chloro-2,4-Dinitro-Chlorobenzene) (DNCB)

Outcome Measures

Primary Outcome Measures

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 55 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No

    Inclusion Criteria

    Patients must have the following:

    • Stage III or IV HIV infection.

    • Provide informed consent.

    Exclusion Criteria

    Co-existing Condition:
    Patients with the following conditions or symptoms are excluded:

    • Kaposi's sarcoma lesions in the proposed treatment sites.

    • Liable to require radiation or chemotherapy during the course of the study.

    • Not likely to survive the length of the study.

    • Obvious ultra-violet-irradiated skin damage in the treatment areas and anyone with recent UV exposure or likely to have such exposure (e.g.:

    • holiday tans obtained in Hawaii, members of UV box tanning salons, etc.) Allergy to lidocaine.

    Concurrent Medication:
    Excluded:
    • Other Immunomodulators.
    Concurrent Treatment:
    Excluded:
    • Radiation.
    Patients with the following are excluded:

    • Kaposi's sarcoma lesions in the proposed treatment sites.

    • Liable to require radiation or chemotherapy during the course of the study.

    • Not likely to survive the length of the study.

    • Obvious ultra-violet-irradiated skin damage in the treatment areas.

    • Allergy to lidocaine.

    Prior Medication:
    Excluded:
    • Prior DNCB therapy.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 San Francisco AIDS Clinic / San Francisco Gen Hosp San Francisco California United States 941102859

    Sponsors and Collaborators

    • University of California, San Francisco

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    , ,
    ClinicalTrials.gov Identifier:
    NCT00002031
    Other Study ID Numbers:
    • 047A
    First Posted:
    Aug 31, 2001
    Last Update Posted:
    Jun 24, 2005
    Last Verified:
    Feb 1, 1990
    Keywords provided by , ,
    Langerhans Cells
    Dinitrochlorobenzene
    Acquired Immunodeficiency Syndrome
    AIDS-Related Complex
    Additional relevant MeSH terms:
    HIV Infections

    Study Results

    No Results Posted as of Jun 24, 2005